Hereditary Hematological Malignancies (HHMs): A New Era of Discovery in MDS and AML (EHA2024)

As knowledge about hereditary hematological malignancies (HHMs) increases, so do the options for better management of these diseases. Please join us in this podcast to hear Dr Kiran Tawana from Addenbrooke’s Hospital in Cambridge, UK, share her insights on this topic. HHMs are syndromes where two or more cases of cytopenia and hematological malignancy (typically MDS/AML) occur within the same family. Dr Tawana discusses the discovery of HHMs and provides advice on how to recognize them in clinical practice, which can be hampered by low penetrance and significant differences in disease latency. Listen to the stories of families affected by HHMs and how the molecular insights gathered from disease evolution in these case studies provide base for improved management of patients in the future. Tune in to hear the recommendations of dr. Tawana on how to optimize testing in clinical pathways and improve outcomes for people with HHMs. Guest: Dr Kiran TawanaThis episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

There are no comments yet.

Please log in to write the first comment.